Sexually transmitted diseases: Difference between revisions
No edit summary |
|||
| Line 12: | Line 12: | ||
==Evaluation== | ==Evaluation== | ||
==Management== | ==Management <ref> https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf </ref>== | ||
*Empiric treatment for [[Gonorrhea]] and [[Chlamydia]]: | |||
**Ceftriaxone 500 mg IM x1 (1g IM for pts > 150 kg) AND | |||
**Doxycycline 100mg PO BID x 7 days (preferred) OR | |||
**Azithromycin 1g PO x 1 OR | |||
**Azithromycin 500 mg PO x 1 and 250mg PO daily x 4 days | |||
*It is important to treat sexual partners for all STDs | *It is important to treat sexual partners for all STDs | ||
**See [[Expedited Partner Therapy]] | **See [[Expedited Partner Therapy]] | ||
Revision as of 07:41, 14 May 2022
Background
- STD Prevalence: HPV > HSV-2 > Trichomonas > Chlamydia > HIV > HBV > Gonorrhea > Syphilis
- STD New infections: HPV > Chlamydia > Trichomonas > Gonorrhea > HSV-2 > Syphilis > HIV > HBV [1]
Clinical Features
STD Visual Diagnosis (Male)
Primary Syphilis
Painless genital ulcer from lymphogranuloma venereum
Inguinal femoral lymphadenopathy (bilateral) from lymphogranuloma venereum
STD Visual Diagnosis (Female)
Differential Diagnosis
Sexually transmitted diseases
- Chancroid
- Chlamydia trachomatis
- Granuloma inguinale
- Hepatitis B
- Herpes Simplex Virus-2
- HIV
- Human papillomavirus
- Lymphogranuloma venereum
- Neisseria gonorrhoeae
- Trichomonas
- Syphilis
Evaluation
Management [2]
- Empiric treatment for Gonorrhea and Chlamydia:
- Ceftriaxone 500 mg IM x1 (1g IM for pts > 150 kg) AND
- Doxycycline 100mg PO BID x 7 days (preferred) OR
- Azithromycin 1g PO x 1 OR
- Azithromycin 500 mg PO x 1 and 250mg PO daily x 4 days
- It is important to treat sexual partners for all STDs
Disposition
See Also
- Human Papillomavirus (HPV)
- Pelvic Inflammatory Disease (PID)
- Ulcerative STDs
- Penile diagnoses
- Pelvic pain
- Expedited Partner Therapy